Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo and Active-controlled, Cross-over, Multi-centre, Study with Five Single Dose Treatment Periods Evaluating Single Administration of Three Doses of Inhaled PT005 in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD), Compared to Open-Label Marketed Formoterol (FORADIL AEROLIZER 'Registered Trade Mark') as an Active Control evaluating the changed in Forced Expiratory Volume.

Trial Profile

A Randomized, Double-blind, Placebo and Active-controlled, Cross-over, Multi-centre, Study with Five Single Dose Treatment Periods Evaluating Single Administration of Three Doses of Inhaled PT005 in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD), Compared to Open-Label Marketed Formoterol (FORADIL AEROLIZER 'Registered Trade Mark') as an Active Control evaluating the changed in Forced Expiratory Volume.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 19 May 2010 Results presented at the annual meeting of the American Thoracic Society.
    • 18 May 2010 Results reported at ATS, according to Pearl Therapeutics media release.
    • 14 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top